According to CheckMate 227, combined immunotherapy has demonstrated durable long-term efficacy benefits over chemotherapy in patients with advanced NSCLC and tumor PD-L1 expression greater than or equal to 1% or less than 1% across nonsquamous and squamous histologies [44]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.